SUV measurements are an indirect marker of PSMA expression density and heterogeneity, which have prognostic value before treatment to assess eligibility and potential chance of treatment benefit but are less suitable for assessing tumor response under therapy since the ligand density does not necessarily correlate with the tumor burden. The gene discussed is FOLH1; the disease is neoplasm.